NCT01195688View on ClinicalTrials.gov

Safety and Tolerability of BI 638683 After Single Rising Oral Doses in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2010

Conditions
Healthy
Interventions
DRUG

BI 638683 or placebo

oral doses given to 6 subjects per dose group

DRUG

Placebo solution

oral doses given to 2 subjects per dose group

Trial Locations (1)

Unknown

1279.1.1 Boehringer Ingelheim Investigational Site, Biberach

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY